Neuropathic Pain: Mechanisms, Management, Novel Therapies

Carlos Herrera
Department of Pain & Neuro Modulation, Andalusian Neuro Institute, Seville, Spain

Corresponding Authors*

Carlos Herrera
Department of Pain & Neuro Modulation, Andalusian Neuro Institute, Seville, Spain
E-mail: cherrera@andeneuro.es

Received: 01-Jul-2025; **Accepted:** 08-Aug-2025; **Published:** 08-Aug-2025

Introduction

This review explores the complex mechanisms underlying neuropathic pain, ranging from peripheral and central sensitization to neuroinflammation and genetic factors. It highlights how these molecular and cellular changes contribute to persistent pain states, offering critical insights into potential targets for novel therapeutic interventions[1].

Here, recent progress in managing neuropathic pain is outlined, covering both pharmacological and non-pharmacological strategies. The emphasis is on personalized approaches, combination therapies, and the emerging role of neuromodulation techniques to improve patient outcomes and significantly reduce pain severity[2].

An updated overview discusses neuromodulation techniques used for neuropathic pain. It specifically addresses spinal cord stimulation, dorsal root ganglion stimulation, and peripheral nerve stimulation, evaluating their efficacy, mechanisms of action, and patient selection criteria for achieving optimal outcomes[3].

Further research delves into the transient receptor potential vanilloid 1 (TRPV1) channel, identifying it as a significant therapeutic target for neuropathic pain. The latest findings on TRPV1's involvement in pain pathways are reviewed, alongside discussions on developing modulators, acknowledging both their promise and the existing challenges in clinical translation[4].

A systematic review evaluates the current evidence for cannabinoids in managing neuropathic pain. It synthesizes findings from various clinical trials and observational studies, providing valuable insights into their efficacy, safety profile, and potential role as an adjunctive treatment, while also recognizing the need for more robust and extensive research[5].

Strategies for reducing opioid reliance in neuropathic pain management are critically explored. This includes various non-opioid pharmacological agents, further discussion of neuromodulation, and integrated care approaches that aim to provide effective pain relief while mitigating the considerable risks associated with long-term opioid use[6].

An updated review highlights the crucial involvement of various immune cells, such as microglia, astrocytes, and T cells, in both the initiation and ongoing maintenance of neuropathic pain. It describes how neuroinflammation, mediated by these specific cells, contributes to neuronal sensitization and pain signaling, suggesting promising new immunomodulatory therapeutic targets[7].

This article reviews the emerging field of gene therapy specifically for neuropathic pain. It discusses diverse gene delivery strategies and identified targets, including those aimed at modulating neurotransmitter systems, neurotrophic factors, and inflammatory pathways, offering a forward-looking perspective on the potential for long-lasting pain relief through genetic interventions[8].

The intriguing connection between the gut microbiome and neuropathic pain, mediated by the gut-brain axis, is explored. It highlights how dysbiosis in the gut can profoundly influence neuroinflammation, neurotransmitter balance, and immune responses, thereby contributing significantly to pain development and modulation, which in turn suggests novel therapeutic avenues[9].

Finally, the potential of stem cell-based therapies for treating neuropathic pain is examined. This review covers various types of stem cells, their proposed mechanisms of action—such as immunomodulation and trophic factor release—and critically assesses the challenges and opportunities for their clinical application in regenerating damaged tissues and effectively modulating pain pathways[10].

Description

Neuropathic pain is a complex condition driven by intricate mechanisms, including peripheral and central sensitization, neuroinflammation, and genetic predispositions [1]. These molecular and cellular changes underpin persistent pain states, pointing toward numerous targets for therapeutic interventions. Effectively managing neuropathic pain involves a blend of pharmacological and non-pharmacological strategies, with an increasing emphasis on personalized care and combination therapies. Neuromodulation techniques, for example, are emerging as key approaches to improve patient outcomes and significantly reduce pain severity [2].

A significant area of focus lies in advanced neuromodulation. Techniques such as spinal cord stimulation, dorsal root ganglion stimulation, and peripheral nerve stimulation are evaluated for their efficacy, underlying

Cite this article: Herrera C,(2025) Neuropathic Pain: Mechanisms, Management, *Novel Therapies. nnr* 07: 164. DOI: 1037532.nnr.2025.7.3.164

mechanisms, and specific patient selection criteria to ensure the best possible results [3]. Beyond neuromodulation, researchers are actively exploring molecular targets. The transient receptor potential vanilloid 1 (TRPV1) channel, for instance, has been identified as a crucial therapeutic target. Latest research reviews TRPV1's role in pain pathways and examines the development of modulators, acknowledging both their promise and the hurdles in bringing them to clinical practice [4].

Innovative therapeutic avenues extend to biological and cellular interventions. Cannabinoids are undergoing systematic review for their role in managing neuropathic pain, with evidence from clinical trials and observational studies providing insights into their efficacy, safety, and potential as an adjunctive treatment, though more robust research is recognized as necessary [5]. The field of gene therapy also presents an emerging frontier, with various gene delivery strategies targeting neurotransmitter systems, neurotrophic factors, and inflammatory pathways, holding promise for long-lasting pain relief [8]. Similarly, stem cell-based therapies are being examined for their potential, covering different stem cell types and their mechanisms, such as immunomodulation and trophic factor release. These therapies offer opportunities for regenerating damaged tissues and modulating pain pathways, despite existing challenges in clinical application [10].

Moreover, the broader biological context of pain is under scrutiny. The critical involvement of immune cells, including microglia, astrocytes, and T cells, in both the initiation and maintenance of neuropathic pain is increasingly understood. Neuroinflammation mediated by these cells contributes directly to neuronal sensitization and pain signaling, suggesting new immunomodulatory therapeutic targets [7]. Furthermore, the fascinating connection between the gut microbiome and neuropathic pain through the gut-brain axis is being uncovered. Dysbiosis in the gut can influence neuroinflammation, neurotransmitter balance, and immune responses, thereby playing a role in pain development and modulation, which opens up new therapeutic possibilities [9].

Strategies for managing neuropathic pain are also evolving to address long-term challenges, notably reducing reliance on opioids. This includes exploring various non-opioid pharmacological agents, further integrating neuromodulation techniques, and developing comprehensive integrated care approaches. The goal is to provide effective pain relief while mitigating the risks associated with prolonged opioid use, thereby ensuring more sustainable and safer treatment paradigms for patients [6].

Conclusion

Neuropathic pain is a complex, chronic condition characterized by diverse underlying mechanisms, including peripheral and central sensitization, neuroinflammation, and genetic influences. Recent advancements highlight a multidisciplinary approach to its management, combining pharmacological and non-pharmacological strategies, with a strong emphasis on personalized and integrated care. Key therapeutic developments include sophisticated neuromodulation techniques like spinal cord and dorsal root ganglion stimulation, which offer promising avenues for pain reduction.

Research also focuses on molecular targets such as the TRPV1 channel, exploring novel modulators, alongside the evaluation of cannabinoids as adjunctive treatments, recognizing the need for further rigorous studies. Emerging biological therapies, including gene therapy and stem cell-based approaches, are being investigated for their potential to provide long-lasting relief by modulating pain pathways and promoting tissue regeneration.

Beyond direct interventions, the understanding of neuropathic pain is expanding to include systemic factors. The critical role of immune cells in neuroinflammation and the intriguing influence of the gut microbiome via the gut-brain axis are revealing new immunomodulatory and microbial-targeted therapeutic strategies. Critically, there's a growing push for opioid-sparing strategies, advocating for non-opioid agents and integrated care to provide effective pain relief while minimizing the risks associated with long-term opioid use. This collective research aims to improve patient outcomes through a deeper understanding of pain mechanisms and the development of innovative, safer treatments.

References

1. Shan C, Hai C, Yang Y. Mechanisms of neuropathic pain: from the clinic to the bench. *Signal Transduct Target Ther.* 2023;8:29.
2. Troels SJ, Nanna BF, *Martin F. Recent advances in the management of neuropathic pain. Pain.* 2023;164 Suppl 1:S6-S13.
3. Alaa AE, Ashley BLR, Ashraf MS. Neuromodulation for Neuropathic Pain: *An Updated Review. Pain Ther.* 2021;10:749-768.
4. Lin M, Bo W, Shan Y. TRPV1 as a Therapeutic Target in Neuropathic Pain: *Recent Advances and Future Perspectives. Front Pharmacol.* 2020;11:593719.
5. Matthias M, Anna W, Lukas R. Cannabinoids in the Management of Neuropathic Pain: *A Systematic Review. J Clin Med.* 2022;11:6386.
6. Jian M, Wei L, Qian S. Opioid-sparing strategies for neuropathic pain: *Current evidence and future directions. Curr Neuropharmacol.* 2023;21:1228-1241.
7. Antonio S, Martina I, Stefano DS. The role of immune cells in neuropathic pain: an updated review. *Neural Regen Res.* 2024;19:251-256.
8. Hao Y, Chao M, Meng Z. Gene therapy for neuropathic pain: *Recent advances and prospects. Brain Res Bull.* 2021;177:110-117.
9. Li L, Jing L, Hong L. The gut microbiome-brain axis in neuropathic pain. *Neurobiol Pain.* 2023;13:100115.
10. Jing W, Hui W, Qian W. Stem Cell-Based Therapies for Neuropathic Pain: *Current State and Future Directions. Cells.* 2021;10:2795.

Cite this article: Herrera C,(2025) Neuropathic Pain: Mechanisms, Management, *Novel Therapies. nnr* 07: 164. DOI: 1037532.nnr.2025.7.3.164